Key facts
- It has raised $7.0M; the latest was Seed Round ($4.5M) in Dec 2025.
- Notable investors include Creative Destruction Lab, SOSV, University of Toronto, Endless Frontier Labs, IndieBio — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for TippingPoint Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for TippingPoint Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TippingPoint Biosciences
Operator of a drug discovery company intended to identify treatments for diseases caused by defects in DNA packaging. The company's platform enables the discovery of new types of drugs that target packaged DNA states unique to a given disease, which includes several cancers, enabling doctors to treat cancers and neurodegenerative diseases and provide stem cell therapies by targeting disease-causing dysfunctional genome packaging.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2022
- Employees
- 7
- Website
- tippingpointbiosciences.com/
- Ownership
- Privately Held (backing)
TippingPoint Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TippingPoint Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TippingPoint Biosciences in its N-PORT filings yet. We sweep new filings monthly.